Thursday, April 3, 2014
University of Bremen group has found a
new target-serine/threonine kinase 4-that can
increase b cell mass and could represent an alternative to
invasive islet cell transplants in patients with diabetes.1 Next,
the team will need to rule out long-term safety issues associated with blocking
challenge will be developing a kinase- and tissue-specific approach to target
Martz, L. SciBX 7(13);
Published online April 3, 2014
1. Ardestani, A. et al. Nat. Med.; published online March
16, 2014; doi:10.1038/nm.3482 Contact: Kathrin Maedler, University of Bremen, Bremen,
Germany e-mail: email@example.com Contact:
Amin Ardestani, same affiliation as above e-mail: firstname.lastname@example.org
2. The Diabetes Control and Complications Trial
Research Group. Ann. Intern.
Med. 128, 517-523 (1998)
3. Johnson, J.D. et al. J. Clin. Invest.
111, 1147-1160 (2003)
4. Brissova, M. et al. J. Biol. Chem. 277, 11225-11232 (2002)
AND INSTITUTIONS MENTIONED
(LSE:AZN; NYSE:AZN), London, U.K.
(Xetra:EVT), Hamburg, Germany
Harvard University, Cambridge, Mass.
Lille 2 University of Health and Law, Lille, France
National Institutes of Health, Bethesda, Md.
Novo Nordisk A/S
(CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark
University of Bremen, Bremen, Germany
University of Copenhagen, Copenhagen, Denmark
University of Illinois at Chicago, Chicago, Ill.